Multivessel Talent Trial
A randomized controlled trial to compare the safety and efficacy of siroliMUs-eLuTIng biodegradable polymer ulTrA-thin stent (Supraflex Cruz) and everolimus-eLuting biodegradable polymer stent (Synergy) in treatmENT for three-vessel coronary artery disease: Multivessel TALENT
Objective of the Study:
To compare clinical outcomes of the novel Supraflex Cruz stent with those of the Synergy stent in patients with three-vessel disease (3VD) undergoing state-of-the-art percutaneous coronary intervention (PCI).
Primary Endpoint
Patient-Oriented Composite Endpoint
Comprising of:
- all cause death
- any stroke, Modified Rankin scale, (MRS ≥1);
- any myocardial infarction (MI)
- any (repeat) revascularization.
Secondary Endpoint
Vessel-Oriented Composite Endpoint
Comprising of:
- vessel-related cardiovascular death,
- vessel-related MI, or clinically and physiologically-indicated target
- vessel revascularisation (CPI-TVR)
1550 Patients
Enrolled
Multi-Centre
European Study
24 Month
Follow-up
Study Details | Multivessel Talent | https://clinicaltrials.gov/study/NCT04390672
Chair & Chief Investigator
Prof. Patrick W. Serruys
Deputy Chair
Prof. Yoshinobu Onuma
Steering Investigator
Dr. Azfar Zaman
Co-Chair
Prof. William Wijns
Principle Steering Investigator
Dr. Helge Moellmann
Steering Investigator
Prof. Manel Sabate